Canton Strategic Holdings (CNTN) Interest Coverage Ratio (2021 - 2025)
Canton Strategic Holdings posted quarterly Interest Coverage Ratio of 576.07 for Q4 2025, up 88.55% year-on-year from 305.52 in Q4 2024, and down 165.47% on a QoQ basis from 217.0 in Q3 2025.
Canton Strategic Holdings (CNTN) has 5 years of Interest Coverage Ratio data on file, last reported at 576.07 in Q4 2025.
- For the quarter ending Q4 2025, Interest Coverage Ratio rose 88.55% year-over-year to 576.07; the trailing twelve-month figure through Mar 2026 stood at 2171.42 (down 200.83% YoY), and the FY2025 full-year result was 311.93, up 65.58% from the prior year.
- Interest Coverage Ratio for Q4 2025 stood at 576.07, down from 217.0 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 201.74 in Q4 2022 and bottomed at 7150.16 in Q4 2023.
- The 5-year median for Interest Coverage Ratio is 331.73 (2025), against an average of 942.5.
- The widest annual swing landed in 2022, when Interest Coverage Ratio soared 51332.86%; it then slumped 52267.26% in 2023.
- A 5-year view of Interest Coverage Ratio shows it stood at 0.39 in 2021, then jumped by 51332.86% to 201.74 in 2022, then slumped by 3644.24% to 7150.16 in 2023, then advanced by 29.63% to 5031.23 in 2024, then surged by 88.55% to 576.07 in 2025.
- The last three Interest Coverage Ratio figures came in at 576.07 (Q4 2025), 217.0 (Q3 2025), and 300.46 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -129.79 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 3.58 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -258.33 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 11.50 |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 49.84 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 3.88 |
| 10 | Canton Strategic Holdings | 643.89 Mn | 602.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -576.07 |
| Sep 30, 2025 | -217.00 |
| Jun 30, 2025 | -300.46 |
| Mar 31, 2025 | -300.63 |
| Dec 31, 2024 | -5,031.23 |
| Sep 30, 2024 | -1,284.67 |
| Jun 30, 2024 | -454.95 |
| Mar 31, 2024 | -499.43 |
| Dec 31, 2023 | -7,150.16 |
| Sep 30, 2023 | -527.77 |
| Jun 30, 2023 | -362.84 |
| Mar 31, 2023 | -442.23 |
| Dec 31, 2022 | 201.74 |
| Mar 31, 2022 | -0.84 |
| Dec 31, 2021 | -0.39 |
| Sep 30, 2021 | -2.29 |
| Jun 30, 2021 | -5.81 |
| Mar 31, 2021 | -9.90 |